Hyperuricemia and adverse outcomes in cardiovascular disease: Potential for therapeutic intervention

American Journal of Cardiovascular Drugs

Volumn 3, Issue 5, 2003, Pages 309-314

  Gavin, Andrew R ^a   Struthers, Allan D ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ALLOPURINOL; ANTICOAGULANT AGENT; ATENOLOL; C REACTIVE PROTEIN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOSARTAN; MACROPHAGE INFLAMMATORY PROTEIN; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; SULFINPYRAZONE; TUMOR NECROSIS FACTOR; URIC ACID; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

AGE; ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE SEVERITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG USE; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; LIVER DISEASE; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PURINE SYNTHESIS; RASH; RAT; REVIEW; RISK FACTOR; SMOKING; STRUCTURE ANALYSIS; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

ALLOPURINOL; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; HYPERURICEMIA; URIC ACID; XANTHINE OXIDASE;

EID: 0242636327     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303050-00001     Document Type: Review

References (78)

1. Liese AD, Hense HW, Lowel H, et al. Association of serum uric acid with all cause and cardiovascular mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organisation Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999; 10: 391-7
2. Leyva F, Anker SD, Swan J, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858-65
3. Wong KYK, MacWalter RS, Fraser HW, et al. Urate predicts subsequent cardiac death in stroke survivors. Eur Heart J 2002 May; 23 (10): 788-93
4. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000 Dec; 36 (6): 1072-8
5. Lehto S, Niskanen L, Ronnemaa T, et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke 1998; 29: 635-9
6. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk of cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13
7. Wannamethee SG, Shaper AG, Whincup PH. Serum mate and the risk of major coronary heart disease events. Heart 1997; 78: 147-53
8. Facchini F, Chen YDI. Hollenbeck CB, et al. Relationship between resistance to insullin-mediated glucose uptake, urinary uric acid clearance and plasma uric acid concentration. JAMA 1991; 266: 3008-11
9. Bengtsson C, Lapidus S, Stendahl C, et al. Hyperuricaemia and risk of cardiovascular disease and overall death: a 12-year follow-up of participants in the population study of Gothenburg, Sweden. Acta Med Scand 1988; 224: 549-55
10. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am J Epidemiol 1985; 121: 11-8
11. Aderman MH, Cohen HM, Kinlighn S, et al. Does treatment-associated increase in uric acid reduce the cardioprotective effect of diuretics in hypertensive patients [abstract]? Am J Hypertens 1998; 2: 16A
12. Iribarren C, Sharp DS, Curb JD, et al. High uric acid: a metabolic marker of coronary heart disease among alcohol abstainer? J Clin Epidemiol 1996; 49: 673-8
13. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670-1
14. Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricaemia in primary and renal hypertension. N Engl J Med 1966; 275: 457-64
15. Langford HG, Blaufox MD, Borhani NO, et al. Is thiazide produced uric acid elevation harmful? Analysis of the data from the hypertension detection and follow-up program. Arch Intern Med 1987; 147: 645-9
16. Tisler A, Pierratos A, Honey JD, et al. Hypertension aggregates in families of kidney store patients with high urinary excretion of uric acid. J Hypertens 1999 Dec; 17 (12 Pt 2): 1853-8
17. Ueno M, Tomita Y, Tsuchihashi T, et al. Clinical alterations in normotensive offspring with parental hypertension. J Hypertens 1998; 6 Suppl. 4: S50-1
18. Hunt SC, Stephenson SH, Hopkins PN, et al. Predictors of an increased future risk of hypertension in Utah. Hypertension 1991; 17: 969-76
19. Capuccio FP, Strazzullo P, Farinaro E, et al. Uric acid metabolism and tubular sodium handling: results from a population-based study. JAMA 1993; 270: 354-9
20. Donskov AS, Balkarov IM, Fadina ZM, et al. Urate affection of kidneys and metabolic disturbances in hypertensive patients. Ter Arkh 1999; 71 (6): 53-6
21. Britten MB, Elsner M, Walter DH, et al. Elevated uric acid levels in hypercholesterolaemia are associated with coronary endothelial dysfunction [abstract 30]. Circulation 1999; 100 Suppl.: I-6
22. Nakanishi N, Tatara K, Nakamura K, et al. Risk factors for the incidence of hyperuricaemia: a 6-year longitudinal study of middle aged Japanese men. Int J Epidemiol 1999 Oct; 28 (5): 888-93
23. Reaving G. Banting lecture 1998: role of insulin resistance in human disease. Diabetes 1998; 37: 1595-607
24. Modan M, Halkin H, Almog S, et al. Hyperinsulinaemia: a link between hypertension, obesity and glucose tolerance. J Clin Invest 1985; 75: 809-17
25. Depres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol 1994; 5: 274-89
26. Boyko EJ, de Courten M, Zimmet PZ, et al. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care 2000 Sep; 23 (9): 1242-8
27. Frohlich M, Imhof A, Berg G, et al. Association between C- reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000 Dec; 23 (12): 1835-9
28. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814-22
29. Kuzuya M, Ando F, Iguchi A, et al. Effect of aging on serum uric acid levels: longitudinal changes in a Japanese population. J Gerentol A Biol Sci Med Sci 2002: 57 (10): M660-4
30. Castelli P, Condemi AM, Brambillasca C, et al. Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol 1995; 25: 119-25
31. Patetsios P, Rodino W, Wisselink W, et al. Identification of uric acid in aortic aneurysms and atherosclerotic artery. Ann N Y Acad Sci 1996; 800: 243-5
32. Bagnati M, Perugini C, Cau C, et al. When and why a water soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999; 340 (Pt 1): 143-52
33. Mustard JF, Murphy EA, Ogryzlo MA. Blood coagulation and platelet economy in subjects with primary gout. CMAJ 1963; 89: 1207-11
34. Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: the Anturane Reinfarction Trial. N Engl J Med 1978 Feb 9; 298 (6): 289-95
35. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1995 Nov 28; 313 (22): 1369-75
36. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. The Anturane Reinfarction Trial Research Group. N Engl J Med 1980 Jan 31; 302 (5): 250-6
37. Gent M, Barnett HJ, Sackett DL, et al. A randomised trial of aspirin and sulfinpyrazone in patients with threatened stroke: results and methodologic issues. Circulation 1980 Dec; 62 (6 Pt 2): V97-105
38. Farquharson C, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-6
39. McCord JM. Oxygen-derived free radicals in postischaemic tissue injury. N Engl J Med 1985; 312: 159-63
40. Hellsten Y, Frandsen U, Ortherblad N, et al. Xanthine oxidase in human skeletal muscle following eccentric exercise: a role in inflammation. J Physiol 1997; 498: 239-48
41. Vina J, Gimeno A, Sastre J, et al. Mechanism of free radical production in exhaustive exercise in humans and rats; role of xanthine oxidase and protection by allopurinol. IUBMB Life 2000 Jun; 49 (6): 539-44
42. DeScheerder IK, van de Kraay AM, Lamers JMJ, et al. Myocardial malondialdehyde and uric acid release after short acting coronary occlusion during coronary angioplasty: Potential mechanism for free radical generation. Am J Cardiol 1991; 68: 392-5
43. Becker BF, Permanetter B, Richardt G, et al. Coronary sinus uric acid as an index of chronic myocardial ischaemia in man. Proceedings of Second International Meeting of the Working Group on Heart Failure. Cologne 1997; May 26: European Society of Cardiology, 1997: 10.
44. Sluiter W, Pietersma A, Lamers JM, et al. Leukocyte adhesion molecules and the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. J Cardiovasc Pharmacol 1993; 22 Suppl. 14: S37-44
45. Gao WD, Liu Y, Marban E. Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle: implications for the mechanism of stunned myocardium. Circulation 1996; 94: 2597-604
46. Xia Y, Zweier JL. Substrate control of free radical generation from xanthine oxidase in the post ischaemic heart. J Biol Chem 1995; 270: 18797-803
47. Bolli R, Jeroudi MO, Patel BS, et al. Marked reduction in of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Circ Res 1989; 65: 607-22
48. Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produces by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest 1996: 98: 2572-9
49. McCord JM. Oxygen-derived free radicals in post-ischaemic tissue injury. N Engl J Med 1985; 312: 159-63
50. Friedl HP, Till GO, Ryan US, et al. Mediator induced activation of xanthine oxidase in endothelial cells. FASEB J 1989; 3: 2512-8
51. Granger DM, Benoit JN, Suzuki M, et al. Leukocyte adherence to venular endothelium during ischaemia-reperfusion. Am J Physiol 1989; 257: G683-8
52. Menger MD, Peikan S, Ateiner D, et al. Microvascular ischaemia-reperfusion injury in striated muscle: significance of 'reflow paradox'. Am J Physiol 1992; 263: H190-6
53. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure. Circulation 2002; 105: 2619-24
54. Cardillo C, Kilcoyne CM, Cannon RO, et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolaemic but not hypertensive patients. Hypertension 1997; 30 (1 Pt 1): 57-63
55. Butler R, Morris AD, Belch JJF, et al. Allopurinol normalises endothelial function in Type 2 diabetes with mild hypertension. Hypertension 2000; 35: 746-51
56. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6
57. Al Suwaidi J, Hamasaki S, Higano S, et al. Long term follow up of patients with mild coronary disease and endothelial dysfunction. Circulation 2000; 101: 948-54
58. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress and the risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8
59. Gokce N, Keaney JF, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105: 1567-72
60. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906
61. Farquharson C, Struthers AD. Spironolactone increases NO bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular AI/A11 conversion in patients with CHF. Circulation 2000; 101: 594-7
62. Egasshira K, Hirooka Y, Kai H. et al. Reduction in serum cholesterol with pravastatin improves endothelium dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation 1994; 89: 2519-24
63. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002, 4
64. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation and plaque stability. Cardiovasc Res 2000; 47 (4): 648-57
65. Chambers DJ, Braimbridge MV, Hearse DJ. Free radicals and cardioplegia: allopurinol and oxypurinol reduce myocardial injury following ischaemia arrest. Ann Thorac Surg 1987; 44: 291-7
66. Stewart JR, Crute SL, Loughlin V, et al. Prevention of free radical-induced myocardial reperfusion injury with allopurinol. J Thorac Cardiovasc Surg 1985; 90: 68-72
67. Suzuki H, DeLano FA, Parks DA, et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A 1998 Apr 14; 95 (8): 4754-9
68. Ekelund UEG, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing induced heart failure. Circ Res 1999; 85: 437-45
69. Ukai T, Cheng C, Tachibana H, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing induced heart failure. Circulation 2001; 103: 750-5
70. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104: 2407-17
71. Leyva F, Chua TP, Anker SD, et al. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism 1998 Sep; 47 (9): 1156-9
72. 2+ sensitising property of xanthine oxidase inhibitors. Circ Res 1998; 83: 423-30
73. Taggart DP, Young V, Hooper J, et al. Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Br Heart J 1994; 71: 177-81
74. Rashid MA, William-Olsson G. Influence of allopurinol on cardiac complications in open heart surgery. Ann Thorac Surg 1991; 52: 127-30
75. Tabayashi K, Suzuki Y, Nagamine S, et al. A clinical trial of allopurinol for myocardial protection. J Thorac Cardiovasc Surg 1991; 101: 713-8
76. Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87 (3): 229-34
77. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
78. Nainggolan L. Losartan impresses in LIFE. Heartwire 2002. Available online from: http://www.theheart.org [Accessed 2002 18 Aug]